Russia Prepares Rollout of Enteromix Cancer Vaccine, Awaits Final Approval

Lead Russia’s Federal Medical and Biological Agency (FMBA) confirmed today that its experimental mRNA cancer vaccine, Enteromix, is ready for use pending Ministry of Health sign-off following successful preclinical trials in Vladivostok.

Nut Graf The vaccine demonstrated high safety and efficacy-achieving tumor shrinkage and slowed progression in animal models-and will first target colorectal cancer. Approval is expected by September 30, marking a potential turning point in Russia’s battle against cancer.

Key Developments

• FMBA head Veronika Skvortsova announced that after several years of research, including three years of mandatory preclinical studies, Enteromix is “now ready for use” and awaiting official clearance at the Eastern Economic Forum.
• Initial trials showed significant tumor reduction (60-80%) and improved survival rates, with no serious side effects reported.
• Colorectal cancer will be the first indication; parallel work is advancing on vaccines for glioblastoma and ocular melanoma.

Technical Highlights Enteromix leverages mRNA technology-similar to that used in COVID-19 vaccines-to train the immune system to recognize and destroy cancer cells. The vaccine is personalized to each patient’s tumor profile, employing AI-driven design algorithms to accelerate production and tailor treatment.

Next Steps Following FMBA endorsement, the Ministry of Health will conduct a final review of trial data before granting approval. If cleared, Enteromix could become the world’s first publicly available personalized mRNA cancer vaccine, offered free to Russian patients under a government-funded program.

Broader Impact The announcement draws global attention as researchers in the UK and US also pursue mRNA cancer therapies. Enteromix’s potential approval may spur accelerated development of personalized oncology solutions and reshape standard cancer treatment protocols.